Bank of Nova Scotia Has $5.74 Million Stock Position in Cencora, Inc. (NYSE:COR)

Bank of Nova Scotia reduced its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 90.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,535 shares of the company's stock after selling 252,288 shares during the period. Bank of Nova Scotia's holdings in Cencora were worth $5,737,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Renaissance Technologies LLC grew its holdings in shares of Cencora by 140.6% in the fourth quarter. Renaissance Technologies LLC now owns 550,700 shares of the company's stock worth $123,731,000 after acquiring an additional 321,800 shares during the period. Twin Capital Management Inc. grew its position in shares of Cencora by 18.0% during the fourth quarter. Twin Capital Management Inc. now owns 14,148 shares of the company's stock worth $3,179,000 after purchasing an additional 2,162 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Cencora by 20.4% in the fourth quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock worth $728,757,000 after buying an additional 550,246 shares in the last quarter. Bank of Montreal Can boosted its holdings in shares of Cencora by 30.5% during the 4th quarter. Bank of Montreal Can now owns 296,033 shares of the company's stock valued at $66,513,000 after purchasing an additional 69,142 shares during the last quarter. Finally, Cerity Partners LLC raised its holdings in shares of Cencora by 1.1% during the 4th quarter. Cerity Partners LLC now owns 39,887 shares of the company's stock worth $8,965,000 after acquiring an additional 430 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Insider Buying and Selling at Cencora

In other Cencora news, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction on Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the sale, the chief accounting officer now owns 20,154 shares of the company's stock, valued at approximately $5,241,249.24. The trade was a 9.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 14,578 shares of the company's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the sale, the chairman now owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. This represents a 4.38 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,675 shares of company stock valued at $8,034,778. 10.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on COR shares. Wells Fargo & Company raised their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Bank of America raised their price target on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Finally, JPMorgan Chase & Co. lifted their price target on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $284.55.

Cencora Price Performance

COR traded up $3.11 during trading on Thursday, reaching $287.55. The stock had a trading volume of 387,302 shares, compared to its average volume of 1,502,071. The stock has a 50 day moving average of $262.38 and a two-hundred day moving average of $246.11. The firm has a market capitalization of $55.76 billion, a price-to-earnings ratio of 40.87, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $296.65.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.77%. Cencora's dividend payout ratio (DPR) is currently 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.